Latest news with #FCAP
Yahoo
27-07-2025
- Business
- Yahoo
Shareholders in First Capital (NASDAQ:FCAP) are in the red if they invested five years ago
Ideally, your overall portfolio should beat the market average. But every investor is virtually certain to have both over-performing and under-performing stocks. So we wouldn't blame long term First Capital, Inc. (NASDAQ:FCAP) shareholders for doubting their decision to hold, with the stock down 29% over a half decade. The falls have accelerated recently, with the share price down 24% in the last three months. This could be related to the recent financial results - you can catch up on the most recent data by reading our company report. Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). While the share price declined over five years, First Capital actually managed to increase EPS by an average of 5.9% per year. So it doesn't seem like EPS is a great guide to understanding how the market is valuing the stock. Or possibly, the market was previously very optimistic, so the stock has disappointed, despite improving EPS. Due to the lack of correlation between the EPS growth and the falling share price, it's worth taking a look at other metrics to try to understand the share price movement. In contrast to the share price, revenue has actually increased by 4.4% a year in the five year period. A more detailed examination of the revenue and earnings may or may not explain why the share price languishes; there could be an opportunity. The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image). We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. Dive deeper into the earnings by checking this interactive graph of First Capital's earnings, revenue and cash flow. What About Dividends? As well as measuring the share price return, investors should also consider the total shareholder return (TSR). The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. We note that for First Capital the TSR over the last 5 years was -17%, which is better than the share price return mentioned above. And there's no prize for guessing that the dividend payments largely explain the divergence! A Different Perspective We're pleased to report that First Capital shareholders have received a total shareholder return of 27% over one year. And that does include the dividend. There's no doubt those recent returns are much better than the TSR loss of 3% per year over five years. We generally put more weight on the long term performance over the short term, but the recent improvement could hint at a (positive) inflection point within the business. If you would like to research First Capital in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company. If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
San Francisco Chronicle
25-07-2025
- Business
- San Francisco Chronicle
First Capital: Q2 Earnings Snapshot
CORYDON, Ind. (AP) — CORYDON, Ind. (AP) — First Capital Inc. (FCAP) on Friday reported profit of $3.8 million in its second quarter. The Corydon, Indiana-based company said it had net income of $1.13 per share. The bank holding company posted revenue of $16.1 million in the period. Its adjusted revenue was $12.4 million. _____
Business Wire
05-06-2025
- Health
- Business Wire
Immersive AI Platform for Pathologists Set to Launch at CAP25 in Orlando
NORTHFIELD, Ill.--(BUSINESS WIRE)--A new virtual artificial intelligence (AI) platform for pathologists will debut at CAP25, September 13-16 in Orlando, to give pathologists experience with the technology. 'It's no risk, no pressure. Just discovery,' said CAP President Donald Karcher, MD, FCAP. 'This initiative is about giving pathologists a trusted environment to evaluate new tools and stay in control of how technology fits into pathology practice.' The College of American Pathologists' (CAP) platform, powered by PathPresenter's technology, will provide CAP members a safe, simulated space to explore cutting-edge AI tools used in pathology. From image analysis to diagnostic support, pathologists can interact with models in realistic patient scenarios without impacting care. 'It's no risk, no pressure. Just discovery,' said CAP President Donald Karcher, MD, FCAP. 'This initiative is about giving pathologists a trusted environment to evaluate new tools and stay in control of how technology fits into pathology practice.' Designed as both an educational tool and a discovery hub, the platform is set to become a go-to destination for pathologists exploring AI in real-world contexts when launched at CAP25. 'We wanted to give pathologists a space to explore how AI models can be used in real-world practice,' said M. E. (Doc) de Baca, MD, FCAP, CAP Council on Informatics and Pathology Innovation Chair. 'This platform not only highlights the AI tools currently available and also offers a glimpse of what's possible as we continue to investigate how AI can support and enhance the practice of pathology.' The platform will feature a slate of AI tools for the pathology community to test drive, with participation from vendors across the industry. Pathologists will be able to engage with real models, not just screenshots or quick demos. It's designed to meet the growing demand for meaningful, hands-on exploration of AI tools in a setting that supports learning and confidence. 'Pathologists are looking for more than marketing jargon,' said Rajendra Singh, MD, FCAP, co-founder of PathPresenter. 'They want evidence. They want to see first-hand how these tools perform, what problems they solve, and how they fit into real pathology workflows. This platform brings together the best of both worlds: innovative AI models and expert users who know how to critically evaluate them.' The initiative is guided by CAP leaders at the forefront of informatics, AI, and digital innovation, bringing deep expertise and a clear focus on what pathologists need most from emerging technologies. About the College of American Pathologists As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, visit the CAP Newsroom, and to watch pathologists at work and see the stories of the patients who trust them with their care. About PathPresenter PathPresenter is an enterprise image management and workflow platform for digital pathology. We are on a mission to democratize access to the world's pathology knowledge by connecting pathologists to the vast expertise of their colleagues globally and providing a practical platform to access and use best-in-class AI models. Founded by dermatopathologist and digital pathology pioneer Dr. Rajendra Singh, PathPresenter's secure, scalable, vendor-agnostic enterprise pathology workflow software has been adopted by tier one medical institutions for clinical care, education, and research, and the company has built a thriving community of tens of thousands of users around the world to easily view and share digital pathology images and knowledge. Learn more at
Yahoo
25-04-2025
- Business
- Yahoo
First Capital: Q1 Earnings Snapshot
CORYDON, Ind. (AP) — CORYDON, Ind. (AP) — First Capital Inc. (FCAP) on Friday reported profit of $3.2 million in its first quarter. The Corydon, Indiana-based company said it had profit of 97 cents per share. The bank holding company posted revenue of $15.2 million in the period. Its adjusted revenue was $11.4 million. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on FCAP at Sign in to access your portfolio
Associated Press
27-03-2025
- Health
- Associated Press
Imagene Laboratory Receives Accreditation From College of American Pathologists
Affirming the Growing Importance of AI-Driven Testing in Cancer Diagnostics PHOENIX, ARIZONA / ACCESS Newswire / March 27, 2025 / The Accreditation Committee of the College of American Pathologists (CAP) has recently awarded accreditation to Imagene Laboratory, Phoenix, Arizona, based on the results of a recent on‐site inspection as part of CAP's Accreditation Programs. Recognized for rigorous and robust standards, CAP accreditation elevates quality and mitigates risk, an important way that laboratories can contribute to improved patient Accreditation - Imagene 'We are proud that the College of American Pathologists has recognized our quality through this accreditation, reflecting our commitment to maintaining the highest standards of excellence in laboratory testing,' said Dan Milner, MD, Imagene's Laboratory Medical Director. 'As a laboratory that provides AI-driven tests, this accreditation not only validates our innovative approach but also assures its reliability and accuracy. Our laboratory, already CLIA-certified, has voluntarily pursued this accreditation to ensure that our quality systems remain best in class.' 'Imagene demonstrates leadership, innovation, and a passionate commitment to standards of excellence while providing the highest quality services, ultimately for patients,' said Richard M. Scanlan, MD, FCAP, chair of the CAP's Council on Accreditation. 'The CAP congratulates Imagene Laboratory on its recent CAP Accreditation.' During the CAP accreditation process, designed to ensure the highest standard of care for all laboratory patients, inspectors examine the laboratory's records and quality control of procedures. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management. These reviews help verify that the Imagene laboratory meets the most recent best practice standards. With over 23,000 laboratory participants, in addition to accreditation, the CAP offers proficiency testing/external quality assessment (PT/EQA) programs, quality improvement tools, and protocols and guidelines to ensure excellence in all areas across the laboratory. Built on a foundation of pathologist expertise, the College of American Pathologists (CAP) partners with laboratories worldwide to elevate the quality of laboratory medicine with best-in-class solutions designed to drive operational, achieve diagnostic, and ensure the best patient care. About the College of American Pathologists As the world's largest organization of board-certified pathologists and a leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, visit the CAP Newsroom, and
